Related Experiment Video
Updated: Jun 19, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Clinical presentations and pathophysiological mechanisms of dystroglycanopathy: advancing therapeutic strategies
Ameya S Walimbe1, Francesco Muntoni2, Kevin P Campbell3
1Division of Pediatric Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Abstract:
Dystroglycanopathies are muscular dystrophies with varying clinical severities, ranging from congenital-onset to adult limb-girdle muscular dystrophy. Dystroglycanopathies are caused by a loss of function of the extracellular matrix receptor α-dystroglycan, a widely expressed cell-surface glycoprotein required for the formation and function of various muscle and non-muscle tissues. In severe clinical presentations, individuals with dystroglycanopathy experience, in addition to muscle weakness and cardiac involvement, structural ocular and CNS malformations, leading to intellectual disability and epilepsy. Currently, management is only symptomatic. Advances in the understanding of the pathophysiology and genetics have identified new therapeutic targets. Emerging therapeutic approaches, including adeno-associated virus gene therapy for limb-girdle muscular dystrophy associated with pathogenic variants in FKRP (the most common form of dystroglycanopathy) and ribitol-based therapies, are being evaluated in clinical trials and could expand treatment options.
Insights
Dystroglycanopathies, a group of muscular dystrophies, stem from impaired α-dystroglycan function. Emerging therapies like gene therapy offer new hope for treating these complex genetic muscle disorders.
Area of Science:
- Biochemistry
- Genetics
- Neurology
Background:
- Dystroglycanopathies are a class of muscular dystrophies characterized by loss of function in the α-dystroglycan receptor.
- This receptor is crucial for muscle and non-muscle tissue integrity.
- Clinical presentations vary widely, from congenital forms to adult limb-girdle muscular dystrophy, often involving severe systemic complications.
Purpose of the Study:
- To review the pathophysiology and genetic underpinnings of dystroglycanopathies.
- To highlight current symptomatic management strategies.
- To explore emerging therapeutic targets and clinical trial advancements.
Main Methods:
- Literature review of pathophysiology and genetics.
- Analysis of current clinical management approaches.
- Survey of ongoing clinical trials for novel therapies.
Main Results:
- Loss of α-dystroglycan function leads to diverse clinical phenotypes, including muscle weakness, cardiac issues, and CNS/ocular malformations.
- Current treatments are primarily symptomatic.
- New therapeutic avenues, including gene therapy and ribitol-based treatments, are under investigation.
Conclusions:
- Understanding dystroglycanopathy mechanisms has identified promising therapeutic targets.
- Gene therapy and other novel approaches show potential to improve treatment options for patients.
- Further research and clinical trials are essential to translate these findings into effective clinical practice.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Parkinson's Disease: Overview
Lysosomal Hydrolases
Proteoglycans
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care

